Single-unit cord blood transplantation may be a curative treatment regimen in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Few disease-specific studies focus on cord blood transplantation in this patient population, according to researchers. For this reason, they set out to assess outcomes in 45 patients with Ph+ALL who underwent bulsulfan-based myeloablative single-unit cord blood transplantation from unrelated donors.
At a median of 20 days, the cumulative incidence for myeloid engraftment was 96%. The rate was significantly better among patients who received higher doses of CD34+ cells.
Researchers reported a 53% incidence rate of graft-versus-host disease, and a 31% incidence rate of grade 2 to grade 4 GVHD. The rate of mortality associated with treatment was 17% on day 100 and 31% at 5 years.
At 5 years, RFS was 31%, EFS was 36% and OS was 44%.
Future studies should be conducted to evaluate strategies to reduce relapse rate after transplant with tyrosine kinase inhibitors, researchers said.
Disclosure: The researchers report no relevant financial disclosures.